Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
30,543,417
-
Share change
-
+2,265,907
-
Total reported value
-
$652,659,906
-
Price per share
-
$21.41
-
Number of holders
-
56
-
Value change
-
+$50,178,002
-
Number of buys
-
40
-
Number of sells
-
7
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q4 2021
As of 31 Dec 2021,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,543,417 shares.
The largest 10 holders included
Cormorant Asset Management, LP, Logos Global Management LP, CITADEL ADVISORS LLC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., EcoR1 Capital, LLC, VANGUARD GROUP INC, Avoro Capital Advisors LLC, BAKER BROS. ADVISORS LP, and FMR LLC.
This page lists
56
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.